Memorial Sloan Kettering Cancer Center
ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLARGO Trial: Polatuzumab Vedotin + Rituximab, Gemcitabine, and Oxaliplatin in R/R DLBCL
By
ASCO 2022 Conference Coverage
FEATURING
Matthew Matasar
By
ASCO 2022 Conference Coverage
FEATURING
Matthew Matasar
Login to view comments.
Click here to Login